search
Back to results

Cardiac Safe Transplants for Systemic Sclerosis (CAST)

Primary Purpose

Systemic Sclerosis, Scleroderma

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Rituximab
Fludarabine
Cyclophosphamide
Mesna
rATG
Methylprednisolone
G-CSF
IVIg
Autologous Stem Cells
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Systemic Sclerosis focused on measuring Autologous Stem Cell Transplantation, Hematopoietic Stem Cell Transplant

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 - 65 years old at the time of pre-transplant evaluation
  2. An established diagnosis of systemic sclerosis
  3. Diffuse cutaneous systemic sclerosis with involvement proximal to the elbow or knee and a modified Rodnan Skin Score of ≥ 14 (see Appendix A)

AND

Any one of the following:

  1. DLCO < 80% of predicted or decrease in lung function (DLCO, DLCO/VA or FVC) of 10% or more over 12 months.
  2. Pulmonary fibrosis or alveolitis on CT scan or chest x-ray (ground glass appearance of alveolitis).
  3. Abnormal EKG (non-specific ST-T wave abnormalities, low QRS voltage, or ventricular hypertrophy), or pericardial effusion or pericardial enhancement without constriction on MRI
  4. Gastrointestinal tract involvement confirmed on radiological study. Radiologic findings of scleroderma are small bowel radiographs showing thickened folds with dilated loops, segmentation, and flocculation +/- diverticula, or pseudodiverticula. A hide-bound appearance may be present (e.g. dilated and crowded circular folds). GI involvement may also be confirmed by D-xylose malabsorption, patulous esophagus on high-resolution computed tomography (HRCT), or esophageal manometry.

OR

Limited cutaneous systemic sclerosis (SSc) (modified Rodnan Skin Score <14) with lung involvement defined as active alveolitis on bronchoalveolar lavage (BAL), ground-glass opacity on CT scan, a DLCO < 80% predicted, or decrease in lung function (DLCO/VA, DLCO, FVC) of 10% or more in last 12 months.

Other Inclusion Criteria for "CAST" Conditioning Regimen (presence of any of the following):

  1. Septal flattening or D-sign on MRI (without deep breathing)
  2. PASP >40 mm Hg or >45 mm Hg with fluid challenge*
  3. mPAP >25 mm Hg or >30 mm Hg with fluid challenge*
  4. Non-ischemia diffuse ventricular hypokinesis or non-ischemia wall hypokinesis

    • Fluid challenge is 1000 ml normal saline over 10 minutes. Fluid challenge will not be done if right atrial pressure is >13 mm Hg at rest or pulmonary capillary wedge pressure is >20 mm Hg at rest.

Exclusion Criteria:

  1. Active ischemic heart disease or untreated coronary artery disease
  2. Untreated life-threatening cardiac arrhythmia on EKG or 24-hour holter
  3. Pericardial effusion > 1 cm on cardiac MRI unless successful pericardiocentesis has been performed
  4. LVEF <35%
  5. End-stage lung disease characterized by TLC<45% of predicted value, or DLCO hemoglobin corrected < 30 % predicted.
  6. Creatinine clearance <40 by 24-hour urine
  7. History of breast implants that have not been removed (unless they cannot be surgically removed due to risks of surgery)
  8. Liver cirrhosis, transaminases >2x of normal limits, or bilirubin > 2.0 unless due to Gilbert's disease
  9. Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment
  10. Prior history of malignancy
  11. Positive pregnancy test, inability or unable to pursue effective means of birth control, or failure to willingly accept or comprehend irreversible sterility as a side effect of therapy
  12. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible
  13. Major hematological abnormalities such as platelet count < 100,000/ul or absolute neutrophil count (ANC) < 1000/ul
  14. HIV positive
  15. Hepatitis B or C positive
  16. PASP >50 mmHg without fluid challenge
  17. mPAP >34 mmHg without fluid challenge
  18. Coronary artery disease not reversed by cardiology and interventional radiology

Sites / Locations

  • Northwestern University, Feinberg School of Medicine
  • Northwestern University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Hematopoietic Stem Cell Transplantation

Arm Description

Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.

Outcomes

Primary Outcome Measures

Change in Skin Score by mRSS
Defined by at least a 25% improvement (decline) in skin score by modified Rodnan skin score (mRSS) if skin score is greater than 14 on enrollment. If skin score is less than 14 on enrollment, improvement is defined by at least a 5% improvement on mRSS. The modified Rodnan skin score (MRSS) is a measure for skin disease in scleroderma and is calculated by summation of skin thickness in 17 different body sites. The scale ranges from at total score of normal skin thickness (0) to severe thickness (51).

Secondary Outcome Measures

Survival of Treatment
Survival of Hematopoietic Stem Cell Transplant during treatment and post treatment up to 1 year.

Full Information

First Posted
June 28, 2018
Last Updated
August 10, 2020
Sponsor
Northwestern University
search

1. Study Identification

Unique Protocol Identification Number
NCT03593902
Brief Title
Cardiac Safe Transplants for Systemic Sclerosis
Acronym
CAST
Official Title
Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Terminated
Why Stopped
PI Sabbatical
Study Start Date
May 17, 2018 (Actual)
Primary Completion Date
October 3, 2019 (Actual)
Study Completion Date
October 9, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
Detailed Description
The autologous hematopoietic stem cell transplant used in this research study is an investigational procedure that uses cyclophosphamide and fludarabine (chemotherapy), rabbit anti-thymocyte globulin (rATG) (a protein that kills the immune cells that are thought to be causing your disease), and rituximab (a biologic drug that targets B cells of your immune system). After use of these treatments, the patient will receive their own previously collected blood stem cells (autologous stem cell transplant). The ability of these experimental treatments to stop relapses and progression (worsening) of your systemic sclerosis will be assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis, Scleroderma
Keywords
Autologous Stem Cell Transplantation, Hematopoietic Stem Cell Transplant

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hematopoietic Stem Cell Transplantation
Arm Type
Experimental
Arm Description
Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
Intervention Type
Drug
Intervention Name(s)
Rituximab
Other Intervention Name(s)
Rituxan
Intervention Description
Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Intervention Type
Drug
Intervention Name(s)
Fludarabine
Other Intervention Name(s)
Fludara
Intervention Description
A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Other Intervention Name(s)
Cytoxan
Intervention Description
A medication used as chemotherapy and to suppress the immune system
Intervention Type
Drug
Intervention Name(s)
Mesna
Other Intervention Name(s)
Mesnex
Intervention Description
A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Intervention Type
Drug
Intervention Name(s)
rATG
Other Intervention Name(s)
Thymoglobulin, Anti-Thymocyte Globulin (Rabbit)
Intervention Description
A rabbit polyclonal antibody to lymphocytes
Intervention Type
Drug
Intervention Name(s)
Methylprednisolone
Other Intervention Name(s)
Solu-Medrol, Depo-Medrol
Intervention Description
A corticosteroid medication used to suppress the immune system and decrease inflammation
Intervention Type
Drug
Intervention Name(s)
G-CSF
Other Intervention Name(s)
Neupogen, Filgrastim, Granix, Zarxio
Intervention Description
A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Intervention Type
Biological
Intervention Name(s)
IVIg
Other Intervention Name(s)
Bivagam, Carimune NF, Gammagard, Privigen, Octagam
Intervention Description
Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
Intervention Type
Biological
Intervention Name(s)
Autologous Stem Cells
Intervention Description
Infusion of patient's own stem cells
Primary Outcome Measure Information:
Title
Change in Skin Score by mRSS
Description
Defined by at least a 25% improvement (decline) in skin score by modified Rodnan skin score (mRSS) if skin score is greater than 14 on enrollment. If skin score is less than 14 on enrollment, improvement is defined by at least a 5% improvement on mRSS. The modified Rodnan skin score (MRSS) is a measure for skin disease in scleroderma and is calculated by summation of skin thickness in 17 different body sites. The scale ranges from at total score of normal skin thickness (0) to severe thickness (51).
Time Frame
Pre Treatment and Post Treatment
Secondary Outcome Measure Information:
Title
Survival of Treatment
Description
Survival of Hematopoietic Stem Cell Transplant during treatment and post treatment up to 1 year.
Time Frame
During Treatment and Post Treatment up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 - 65 years old at the time of pre-transplant evaluation An established diagnosis of systemic sclerosis Diffuse cutaneous systemic sclerosis with involvement proximal to the elbow or knee and a modified Rodnan Skin Score of ≥ 14 (see Appendix A) AND Any one of the following: DLCO < 80% of predicted or decrease in lung function (DLCO, DLCO/VA or FVC) of 10% or more over 12 months. Pulmonary fibrosis or alveolitis on CT scan or chest x-ray (ground glass appearance of alveolitis). Abnormal EKG (non-specific ST-T wave abnormalities, low QRS voltage, or ventricular hypertrophy), or pericardial effusion or pericardial enhancement without constriction on MRI Gastrointestinal tract involvement confirmed on radiological study. Radiologic findings of scleroderma are small bowel radiographs showing thickened folds with dilated loops, segmentation, and flocculation +/- diverticula, or pseudodiverticula. A hide-bound appearance may be present (e.g. dilated and crowded circular folds). GI involvement may also be confirmed by D-xylose malabsorption, patulous esophagus on high-resolution computed tomography (HRCT), or esophageal manometry. OR Limited cutaneous systemic sclerosis (SSc) (modified Rodnan Skin Score <14) with lung involvement defined as active alveolitis on bronchoalveolar lavage (BAL), ground-glass opacity on CT scan, a DLCO < 80% predicted, or decrease in lung function (DLCO/VA, DLCO, FVC) of 10% or more in last 12 months. Other Inclusion Criteria for "CAST" Conditioning Regimen (presence of any of the following): Septal flattening or D-sign on MRI (without deep breathing) PASP >40 mm Hg or >45 mm Hg with fluid challenge* mPAP >25 mm Hg or >30 mm Hg with fluid challenge* Non-ischemia diffuse ventricular hypokinesis or non-ischemia wall hypokinesis Fluid challenge is 1000 ml normal saline over 10 minutes. Fluid challenge will not be done if right atrial pressure is >13 mm Hg at rest or pulmonary capillary wedge pressure is >20 mm Hg at rest. Exclusion Criteria: Active ischemic heart disease or untreated coronary artery disease Untreated life-threatening cardiac arrhythmia on EKG or 24-hour holter Pericardial effusion > 1 cm on cardiac MRI unless successful pericardiocentesis has been performed LVEF <35% End-stage lung disease characterized by TLC<45% of predicted value, or DLCO hemoglobin corrected < 30 % predicted. Creatinine clearance <40 by 24-hour urine History of breast implants that have not been removed (unless they cannot be surgically removed due to risks of surgery) Liver cirrhosis, transaminases >2x of normal limits, or bilirubin > 2.0 unless due to Gilbert's disease Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment Prior history of malignancy Positive pregnancy test, inability or unable to pursue effective means of birth control, or failure to willingly accept or comprehend irreversible sterility as a side effect of therapy Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible Major hematological abnormalities such as platelet count < 100,000/ul or absolute neutrophil count (ANC) < 1000/ul HIV positive Hepatitis B or C positive PASP >50 mmHg without fluid challenge mPAP >34 mmHg without fluid challenge Coronary artery disease not reversed by cardiology and interventional radiology
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Burt, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University, Feinberg School of Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32612255
Citation
Burt RK, Han X, Quigley K, Arnautovic I, Shah SJ, Lee DC, Freed BH, Jovanovic B, Helenowski IB. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transplant. 2021 Jan;56(1):50-59. doi: 10.1038/s41409-020-0978-2. Epub 2020 Jul 1.
Results Reference
derived

Learn more about this trial

Cardiac Safe Transplants for Systemic Sclerosis

We'll reach out to this number within 24 hrs